Multiple forces, including lessons from COVID-19, are driving biopharma R&D toward faster development cycles and more decentralized R&D activities across geographies and contract research and development organizations. These two shifts seem to be at polar odds with one another. Decentralized R&D means more difficult communication and possibly more opportunity for error and delay. On the other hand, faster cycles could bring more intensive communication and data needs and more localization for efficiency and reliability. Join our expert panel to learn how innovations in team structure, skillsets, process technology, and digital technology help address these needs.